Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network.
Antimicrobial resistance of Streptococcus pneumoniae in France is closely monitored by the pneumococcus surveillance network, founded in 1995, which collects data from regional observatories (Observatoire Régionaux du Pneumocoque [ORP]). In 2007, 23 ORPs analyzed the antibiotic susceptibility of 5,302 isolates of S. pneumoniae recovered in France from cerebrospinal fluid, blood, middle ear fluid, and pleural fluid, as well as from adult respiratory samples. The study showed that 38.2% of the strains were nonsusceptible to penicillin, 19.3% nonsusceptible to amoxicillin, and 10.5% nonsusceptible to cefotaxime. The percentage of pneumococcus nonsusceptible to penicillin varied according to both the sample and the age of the patient (child/adult): blood (27.8%/32.5%), cerebrospinal fluid (33.7%/34.6%), middle ear fluid (60.2%/27.5%), and pleural fluid (50.0%/31.0%). Between 2003 and 2007, the frequency of penicillin resistance in invasive pneumococcal disease gradually decreased from 46.4% to 29.0% in children and from 43.8% to 32.7% in adults. This decrease coincided with the introduction of a seven-valent pneumococcal conjugate vaccine into immunization programs and with a general reduction in levels of antibiotic consumption in France.
Kempf
Marie
M
Observatoire Régional du Pneumocoque (ORP) Pays de Loire, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Baraduc
Regine
R
Bonnabau
Henri
H
Brun
Michel
M
Chabanon
Gerard
G
Chardon
Hubert
H
Croizé
Jacques
J
Demachy
Marie Claude
MC
Donnio
Pierre-Yves
PY
Dupont
Philippe
P
Fosse
Thierry
T
Gibel
Laurent
L
Gravet
Alain
A
Grignon
Bernadette
B
Hadou
Tahar
T
Hamdad
Farida
F
Joly-Guillou
Marie-Laure
ML
Koeck
Jean Louis
JL
Maugein
Jeanne
J
Péchinot
Andre
A
Ploy
Marie-Cecile
MC
Raymond
Josette
J
Ros
Alain
A
Roussel-Delvallez
Micheline
M
Segonds
Christine
C
Vergnaud
Michel
M
Vernet-Garnier
Veronique
V
Lepoutre
Agnes
A
Gutmann
Laurent
L
Varon
Emmanuelle
E
Lanotte
Philippe
P
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024901:Drug Resistance, Multiple, Bacterial; D005602:France / Q000453:epidemiology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D008826:Microbial Sensitivity Tests; D011008:Pneumococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D011159:Population Surveillance / Q000379:methods; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines